Notice of Class Action Lawsuit for Medpace Stockholders
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 43 minutes ago
0mins
Should l Buy MEDP?
Source: Globenewswire
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Medpace stock between April 22, 2025, and February 9, 2026, that they must apply to be lead plaintiff by June 8, 2026, to represent other investors in the class action lawsuit.
- Lawsuit Background: The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rates during the class period, leading investors to have overly optimistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its significant expertise in this field.
- Investor Action Advice: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on joining the class action, with no upfront fees required, ensuring proper representation in the legal proceedings.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MEDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 417.290
Low
462.00
Averages
569.17
High
660.00
Current: 417.290
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Notice of Class Action Lawsuit for Medpace Stockholders
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Medpace stock between April 22, 2025, and February 9, 2026, that they must apply to be lead plaintiff by June 8, 2026, to represent other investors in the class action lawsuit.
- Lawsuit Background: The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rates during the class period, leading investors to have overly optimistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its significant expertise in this field.
- Investor Action Advice: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on joining the class action, with no upfront fees required, ensuring proper representation in the legal proceedings.
See More
Medpace Holdings Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Medpace Holdings, alleging that the company and certain officers may have engaged in securities fraud or other unlawful business practices, with investors urged to apply as Lead Plaintiff by June 8, 2026, highlighting serious concerns over corporate governance and compliance.
- Earnings Miss: On February 9, 2026, Medpace reported a book-to-bill ratio of 1.04 for Q4 2025, significantly below company guidance, indicating weak business growth that could undermine future investor confidence.
- Stock Price Plunge: Following the disappointing earnings report, Medpace's stock price fell by $84.30, or 15.9%, closing at $446.05 on February 10, 2026, reflecting market concerns regarding the company's financial health.
- Legal Implications: The lawsuit could expose Medpace to substantial damages, as Pomerantz LLP, a prominent firm in securities litigation, has historically secured multimillion-dollar settlements for victims, indicating that the company may face serious legal and financial risks.
See More
Multiple Companies Face Class Action Lawsuits
- Pinterest Lawsuit Overview: Pinterest, Inc. is accused of failing to disclose risks of declining advertising revenues during the class period from February 2025 to February 2026, potentially leading to restructuring and negatively impacting future financial performance.
- New Era Energy Violations: New Era Energy & Digital, Inc. faces allegations of overstating progress on its Texas data center project and engaging in fraudulent schemes to evade liabilities, which could result in materially misleading financial results and erode investor confidence.
- Gossamer Bio Study Failure: Gossamer Bio, Inc. failed to meet the primary endpoint in its clinical trial from 2025 to 2026, as patients performed well on placebo, leading to accusations that prior positive statements were misleading, potentially harming its market reputation.
- Medpace Holdings Performance Inflation: Medpace Holdings, Inc. is accused of making false statements regarding its projected book-to-bill ratio for Q4 2025, failing to adequately assess the impact of cancellations, which may lead to diminished investor confidence in the company's future performance.
See More
Medpace Faces Securities Fraud Allegations, Stock Drops 16%
- Securities Fraud Allegations: Medpace Holdings Inc. is facing securities fraud allegations for allegedly understating cancellation rates and overstating its book-to-bill ratio, resulting in a 16% stock drop in a single day, from $530.35 to $446.05, with investors urged to act by June 8, 2026.
- Legal Action Developments: Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Medpace and certain executives, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, with the case pending in the U.S. District Court for the Southern District of Ohio, potentially impacting the company's future legal liabilities and financial health.
- Misleading Financial Data: On February 9, 2026, Medpace reported a decline in its book-to-bill ratio to 1.04 for Q4 2025 due to increased cancellations, contradicting previous statements about strong award notifications, which may lead to a loss of investor confidence.
- Executive Changes Impact: The resignation of President Jesse Geiger has heightened market concerns regarding Medpace's future, contributing to a further 23% stock decline during afternoon trading on April 23, 2026, reflecting investor skepticism about the company's governance and operational transparency.
See More
Medpace Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Medpace Holdings Inc. and certain executives, alleging securities fraud related to the company's misleading statements about cancellation rates and book-to-bill ratios, which led to a significant 15.9% stock drop on February 9, 2026.
- Stock Price Volatility: Following the financial results announcement on February 9, Medpace's stock plummeted from $530.35 to $446.05 per share, reflecting investor concerns over the company's financial health and negatively impacting market expectations for future performance.
- Management Changes: Amid the lawsuit, Medpace's President Jesse Geiger announced his resignation, raising further concerns about the company's governance and management stability, which could lead to a decline in investor confidence.
- Legal Implications: Investors have until June 8, 2026, to apply to lead the case, and if the lawsuit succeeds, it could have significant repercussions on Medpace's financial standing, exacerbating stock price volatility.
See More
Reminder for Medpace Stock Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to protect their rights in the ongoing class action lawsuit.
- Fee Arrangement: Investors participating in the lawsuit will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, thereby reducing financial barriers and encouraging more affected investors to join.
- Lawsuit Background: The lawsuit alleges that Medpace made false or misleading statements regarding its backlog cancellation rates during the class period, leading investors to have overly optimistic growth expectations that ultimately resulted in financial losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
Notice of Class Action Lawsuit for Medpace Stockholders
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Medpace stock between April 22, 2025, and February 9, 2026, that they must apply to be lead plaintiff by June 8, 2026, to represent other investors in the class action lawsuit.
- Lawsuit Background: The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rates during the class period, leading investors to have overly optimistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its significant expertise in this field.
- Investor Action Advice: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on joining the class action, with no upfront fees required, ensuring proper representation in the legal proceedings.
See More
Medpace Holdings Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Medpace Holdings, alleging that the company and certain officers may have engaged in securities fraud or other unlawful business practices, with investors urged to apply as Lead Plaintiff by June 8, 2026, highlighting serious concerns over corporate governance and compliance.
- Earnings Miss: On February 9, 2026, Medpace reported a book-to-bill ratio of 1.04 for Q4 2025, significantly below company guidance, indicating weak business growth that could undermine future investor confidence.
- Stock Price Plunge: Following the disappointing earnings report, Medpace's stock price fell by $84.30, or 15.9%, closing at $446.05 on February 10, 2026, reflecting market concerns regarding the company's financial health.
- Legal Implications: The lawsuit could expose Medpace to substantial damages, as Pomerantz LLP, a prominent firm in securities litigation, has historically secured multimillion-dollar settlements for victims, indicating that the company may face serious legal and financial risks.
See More
Multiple Companies Face Class Action Lawsuits
- Pinterest Lawsuit Overview: Pinterest, Inc. is accused of failing to disclose risks of declining advertising revenues during the class period from February 2025 to February 2026, potentially leading to restructuring and negatively impacting future financial performance.
- New Era Energy Violations: New Era Energy & Digital, Inc. faces allegations of overstating progress on its Texas data center project and engaging in fraudulent schemes to evade liabilities, which could result in materially misleading financial results and erode investor confidence.
- Gossamer Bio Study Failure: Gossamer Bio, Inc. failed to meet the primary endpoint in its clinical trial from 2025 to 2026, as patients performed well on placebo, leading to accusations that prior positive statements were misleading, potentially harming its market reputation.
- Medpace Holdings Performance Inflation: Medpace Holdings, Inc. is accused of making false statements regarding its projected book-to-bill ratio for Q4 2025, failing to adequately assess the impact of cancellations, which may lead to diminished investor confidence in the company's future performance.
See More
Medpace Faces Securities Fraud Allegations, Stock Drops 16%
- Securities Fraud Allegations: Medpace Holdings Inc. is facing securities fraud allegations for allegedly understating cancellation rates and overstating its book-to-bill ratio, resulting in a 16% stock drop in a single day, from $530.35 to $446.05, with investors urged to act by June 8, 2026.
- Legal Action Developments: Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Medpace and certain executives, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, with the case pending in the U.S. District Court for the Southern District of Ohio, potentially impacting the company's future legal liabilities and financial health.
- Misleading Financial Data: On February 9, 2026, Medpace reported a decline in its book-to-bill ratio to 1.04 for Q4 2025 due to increased cancellations, contradicting previous statements about strong award notifications, which may lead to a loss of investor confidence.
- Executive Changes Impact: The resignation of President Jesse Geiger has heightened market concerns regarding Medpace's future, contributing to a further 23% stock decline during afternoon trading on April 23, 2026, reflecting investor skepticism about the company's governance and operational transparency.
See More
Medpace Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Medpace Holdings Inc. and certain executives, alleging securities fraud related to the company's misleading statements about cancellation rates and book-to-bill ratios, which led to a significant 15.9% stock drop on February 9, 2026.
- Stock Price Volatility: Following the financial results announcement on February 9, Medpace's stock plummeted from $530.35 to $446.05 per share, reflecting investor concerns over the company's financial health and negatively impacting market expectations for future performance.
- Management Changes: Amid the lawsuit, Medpace's President Jesse Geiger announced his resignation, raising further concerns about the company's governance and management stability, which could lead to a decline in investor confidence.
- Legal Implications: Investors have until June 8, 2026, to apply to lead the case, and if the lawsuit succeeds, it could have significant repercussions on Medpace's financial standing, exacerbating stock price volatility.
See More
Reminder for Medpace Stock Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to protect their rights in the ongoing class action lawsuit.
- Fee Arrangement: Investors participating in the lawsuit will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, thereby reducing financial barriers and encouraging more affected investors to join.
- Lawsuit Background: The lawsuit alleges that Medpace made false or misleading statements regarding its backlog cancellation rates during the class period, leading investors to have overly optimistic growth expectations that ultimately resulted in financial losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
